Taken alongside Prolia/Xgeva, the brands account for well over 40% of Amgen's current revenues. Other companies working on biosimilar versions of denosumab include Samsung Bioepis, Celltrion, and ...

Prolia is the brand name for the most common medication used to treat osteoporosis in Australia. It's administered by injection every six months and shouldn't be late or skipped. CHF is concerned that ...